Triazolam



Triazolam





(trye ay’ zoe lam)

Apo-Triazo (CAN), Gen-Triazolam (CAN), Halcion

PREGNANCY CATEGORY X

CONTROLLED SUBSTANCE C-IV


Drug Classes

Benzodiazepine

Sedative-hypnotic


Therapeutic Actions

Exact mechanisms of action not understood; acts mainly at subcortical levels of the CNS, leaving the cortex relatively unaffected; main sites of action may be the limbic system and mesencephalic reticular formation; benzodiazepines potentiate the effects of GABA, an inhibitory neurotransmitter.


Indications



  • Insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, or early morning awakening (short-term use: 7–10 days)


  • Acute or chronic medical situations requiring restful sleep



Available Forms

Tablets—0.125, 0.25 mg


Dosages

Adults

0.125–0.25 mg PO before retiring. May be increased to 0.5 mg if needed. Do not exceed 0.5 mg/day.

Pediatric patients

Not for use in patients younger than 18 yr.

Geriatric or debilitated patients

Initially, 0.125–0.25 mg PO. Adjust as needed and tolerated. Do not exceed 0.25 mg/day.


Pharmacokinetics















Route Onset Peak
Oral Varies 30 min–2 hr

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Triazolam

Full access? Get Clinical Tree

Get Clinical Tree app for offline access